- Home
- WAI vs BOLD Comparison
WAI vs BOLD Comparison
Compare WAI & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WAI
- BOLD
- Stock Information
- Founded
- WAI 2018
- BOLD 2018
- Country
- WAI China
- BOLD United States
- Employees
- WAI N/A
- BOLD N/A
- Industry
- WAI
- BOLD
- Sector
- WAI
- BOLD
- Exchange
- WAI NYSE
- BOLD Nasdaq
- Market Cap
- WAI 28.2M
- BOLD 30.3M
- IPO Year
- WAI 2023
- BOLD 2024
- Fundamental
- Price
- WAI $2.00
- BOLD $1.17
- Analyst Decision
- WAI
- BOLD Buy
- Analyst Count
- WAI 0
- BOLD 3
- Target Price
- WAI N/A
- BOLD $4.00
- AVG Volume (30 Days)
- WAI 78.6K
- BOLD 79.0K
- Earning Date
- WAI 06-17-2025
- BOLD 05-09-2025
- Dividend Yield
- WAI N/A
- BOLD N/A
- EPS Growth
- WAI N/A
- BOLD N/A
- EPS
- WAI N/A
- BOLD N/A
- Revenue
- WAI $3,750,352.00
- BOLD N/A
- Revenue This Year
- WAI N/A
- BOLD N/A
- Revenue Next Year
- WAI N/A
- BOLD N/A
- P/E Ratio
- WAI N/A
- BOLD N/A
- Revenue Growth
- WAI N/A
- BOLD N/A
- 52 Week Low
- WAI $1.60
- BOLD $1.06
- 52 Week High
- WAI $20.00
- BOLD $10.13
- Technical
- Relative Strength Index (RSI)
- WAI N/A
- BOLD N/A
- Support Level
- WAI N/A
- BOLD N/A
- Resistance Level
- WAI N/A
- BOLD N/A
- Average True Range (ATR)
- WAI 0.00
- BOLD 0.00
- MACD
- WAI 0.00
- BOLD 0.00
- Stochastic Oscillator
- WAI 0.00
- BOLD 0.00
About WAI TOP KINGWIN LTD
Top KingWin Ltd operates as a corporate business training and consulting company, providing personal and management training and financial consulting services. It provides a number of essential business services in China to young and emerging companies including corporate business training services, which mainly focus on advanced knowledge and new perspectives on the capital markets; corporate consulting services, which mainly focus on various aspects of fundraising, and advisory and transaction services. Its main clients are entrepreneurs and executives in China's small and medium enterprises (SMEs).
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.